Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE-HL
NCT06745076Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Mar 2025
- Primary completion
- Jan 2032
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, pegylated liposomal doxorubicin, vinblastine, dacarbazine in Hodgkin lymphoma (HL), sponsored by University of Washington. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT06745076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745076.